Literature DB >> 24176979

Identification of retinal ganglion cell neuroprotection conferred by platelet-derived growth factor through analysis of the mesenchymal stem cell secretome.

Thomas V Johnson1, Nicholas W DeKorver, Victoria A Levasseur, Andrew Osborne, Alessia Tassoni, Barbara Lorber, Janosch P Heller, Rafael Villasmil, Natalie D Bull, Keith R Martin, Stanislav I Tomarev.   

Abstract

The development of neuroprotective strategies to attenuate retinal ganglion cell death could lead to novel therapies for chronic optic neuropathies such as glaucoma. Intravitreal transplantation of mesenchymal stem cells slows retinal ganglion cell death in models of optic nerve injury, but the mechanism of action remains unclear. Here we characterized the neuroprotective effects of mesenchymal stem cells and mesenchymal stem cell-derived factors in organotypic retinal explant culture and an in vivo model of ocular hypertensive glaucoma. Co-culture of rat and human bone marrow-derived mesenchymal stem cells with retinal explants increased retinal ganglion cell survival, after 7 days ex vivo, by ∼2-fold and was associated with reduced apoptosis and increased nerve fibre layer and inner plexiform layer thicknesses. These effects were not demonstrated by co-culture with human or mouse fibroblasts. Conditioned media from mesenchymal stem cells conferred neuroprotection, suggesting that the neuroprotection is mediated, at least partly, by secreted factors. We compared the concentrations of 29 factors in human mesenchymal stem cell and fibroblast conditioned media, and identified 11 enriched in the mesenchymal stem cell secretome. Treatment of retinal explants with a cocktail of these factors conferred retinal ganglion cell neuroprotection, with factors from the platelet-derived growth factor family being the most potent. Blockade of platelet-derived growth factor signalling with neutralizing antibody or with small molecule inhibitors of platelet-derived growth factor receptor kinase or downstream phosphatidylinositol 3 kinase eliminated retinal ganglion cell neuroprotection conferred by mesenchymal stem cell co-culture. Intravitreal injection of platelet-derived growth factor -AA or -AB led to profound optic nerve neuroprotection in vivo following experimental induction of elevated intraocular pressure. These data demonstrate that mesenchymal stem cells secrete a number of neuroprotective proteins and suggest that platelet-derived growth factor secretion in particular may play an important role in mesenchymal stem cell-mediated retinal ganglion cell neuroprotection. Furthermore, platelet-derived growth factor may represent an independent target for achieving retinal ganglion cell neuroprotection.

Entities:  

Keywords:  glaucoma; mesenchymal stem cell; neuroprotection; platelet derived growth factor; retinal ganglion cell

Mesh:

Substances:

Year:  2013        PMID: 24176979      PMCID: PMC3914467          DOI: 10.1093/brain/awt292

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  49 in total

1.  Effects of direct transplantation of multipotent mesenchymal stromal/stem cells into the demyelinated spinal cord.

Authors:  D P J Hunt; K A Irvine; D J Webber; D A S Compston; W F Blakemore; S Chandran
Journal:  Cell Transplant       Date:  2008       Impact factor: 4.064

2.  Stem cells for neuroprotection in glaucoma.

Authors:  N D Bull; T V Johnson; K R Martin
Journal:  Prog Brain Res       Date:  2008       Impact factor: 2.453

Review 3.  Harnessing the mesenchymal stem cell secretome for the treatment of cardiovascular disease.

Authors:  Sudhir H Ranganath; Oren Levy; Maneesha S Inamdar; Jeffrey M Karp
Journal:  Cell Stem Cell       Date:  2012-03-02       Impact factor: 24.633

Review 4.  Glaucoma 2.0: neuroprotection, neuroregeneration, neuroenhancement.

Authors:  Elma E Chang; Jeffrey L Goldberg
Journal:  Ophthalmology       Date:  2012-02-18       Impact factor: 12.079

Review 5.  The molecular basis of retinal ganglion cell death in glaucoma.

Authors:  Mohammadali Almasieh; Ariel M Wilson; Barbara Morquette; Jorge Luis Cueva Vargas; Adriana Di Polo
Journal:  Prog Retin Eye Res       Date:  2011-12-04       Impact factor: 21.198

Review 6.  Translational neuroprotection research in glaucoma: a review of definitions and principles.

Authors:  Robert J Casson; Glyn Chidlow; Andreas Ebneter; John P M Wood; Jonathan Crowston; Ivan Goldberg
Journal:  Clin Exp Ophthalmol       Date:  2011-04-27       Impact factor: 4.207

7.  Effects of bone-marrow mesenchymal stem cells transplanted into vitreous cavity of rat injured by ischemia/reperfusion.

Authors:  Na Li; Xiao-rong Li; Jia-qin Yuan
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2008-12-16       Impact factor: 3.117

8.  PDGF- and insulin/IGF-1-specific distinct modes of class IA PI 3-kinase activation in normal rat retinas and RGC-5 retinal ganglion cells.

Authors:  Swarajit K Biswas; Yan Zhao; Arumugam Nagalingam; Thomas W Gardner; Lakshman Sandirasegarane
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-04-17       Impact factor: 4.799

9.  Pigment epithelium-derived factor released by Müller glial cells exerts neuroprotective effects on retinal ganglion cells.

Authors:  Jan Darius Unterlauft; Wolfram Eichler; Konstantin Kuhne; Xiu Mei Yang; Yousef Yafai; Peter Wiedemann; Andreas Reichenbach; Thomas Claudepierre
Journal:  Neurochem Res       Date:  2012-03-13       Impact factor: 3.996

10.  Human embryonic mesenchymal stem cell-derived conditioned medium rescues kidney function in rats with established chronic kidney disease.

Authors:  Arianne van Koppen; Jaap A Joles; Bas W M van Balkom; Sai Kiang Lim; Dominique de Kleijn; Rachel H Giles; Marianne C Verhaar
Journal:  PLoS One       Date:  2012-06-19       Impact factor: 3.240

View more
  79 in total

1.  A Novel ImageJ Macro for Automated Cell Death Quantitation in the Retina.

Authors:  Daniel E Maidana; Pavlina Tsoka; Bo Tian; Bernard Dib; Hidetaka Matsumoto; Keiko Kataoka; Haijiang Lin; Joan W Miller; Demetrios G Vavvas
Journal:  Invest Ophthalmol Vis Sci       Date:  2015-10       Impact factor: 4.799

Review 2.  Using Electrical Stimulation to Enhance the Efficacy of Cell Transplantation Therapies for Neurodegenerative Retinal Diseases: Concepts, Challenges, and Future Perspectives.

Authors:  Abby Leigh Manthey; Wei Liu; Zhi Xin Jiang; Marcus Hiu Kong Lee; Jian Ji; Kwok-Fai So; Jimmy Shiu Ming Lai; Vincent Wing Hong Lee; Kin Chiu
Journal:  Cell Transplant       Date:  2017-02-03       Impact factor: 4.064

3.  Myocilin regulates cell proliferation and survival.

Authors:  Myung Kuk Joe; Heung Sun Kwon; Radu Cojocaru; Stanislav I Tomarev
Journal:  J Biol Chem       Date:  2014-02-22       Impact factor: 5.157

Review 4.  Exciting directions in glaucoma.

Authors:  Carol A Rasmussen; Paul L Kaufman
Journal:  Can J Ophthalmol       Date:  2014-12       Impact factor: 1.882

Review 5.  Protecting retinal ganglion cells.

Authors:  T Z Khatib; K R Martin
Journal:  Eye (Lond)       Date:  2017-01-13       Impact factor: 3.775

6.  Neuroprotective effects of BDNF and GDNF in intravitreally transplanted mesenchymal stem cells after optic nerve crush in mice.

Authors:  Zong-Li Hu; Ni Li; Xin Wei; Li Tang; Ting-Hua Wang; Xiao-Ming Chen
Journal:  Int J Ophthalmol       Date:  2017-01-18       Impact factor: 1.779

7.  Ex Vivo Model of Spontaneous Neuroretinal Degeneration for Evaluating Stem Cells' Paracrine Properties.

Authors:  Ivan Fernandez-Bueno; Ricardo Usategui-Martin
Journal:  Methods Mol Biol       Date:  2021

Review 8.  Roles of exosomes in the normal and diseased eye.

Authors:  Mikael Klingeborn; W Michael Dismuke; Catherine Bowes Rickman; W Daniel Stamer
Journal:  Prog Retin Eye Res       Date:  2017-04-29       Impact factor: 21.198

Review 9.  Mesenchymal Stem Cell-Macrophage Choreography Supporting Spinal Cord Repair.

Authors:  Inés Maldonado-Lasunción; Joost Verhaagen; Martin Oudega
Journal:  Neurotherapeutics       Date:  2018-07       Impact factor: 7.620

Review 10.  Evaluating retinal ganglion cell loss and dysfunction.

Authors:  Ben Mead; Stanislav Tomarev
Journal:  Exp Eye Res       Date:  2016-08-12       Impact factor: 3.467

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.